Oncopeptides is a science and data driven company. We are innovative and curious, and committed to bringing innovation to patients with rare hematological diseases. We are passionate to make a difference for patients who have an urgent need for better treatment options.
Two Unique Technology Platforms
Oncopeptides is developing innovative drug candidates for difficult to treat
haematological diseases. The development is built on our platforms for
Peptide Drug Conjugate (PDC), and Small Polypeptide based Killer Engagers
(SPiKE), and allow us to build a robust pipeline, and potentially expand into
Multiple myeloma is a cancer of the bone marrow that results in production of abnormal blood plasma cells.